si-miao-yong-an decoction

traditional Chinese herbal formulation consisted of (Lonicera japonica, scrophularia ningpoensis, angelica sinesis, glycyrrhiza uralensis) Protects Against Cardiac Hypertrophy and Fibrosis in Isoprenaline-Induced Heart Failure

Also Known As:

Networked: 25 relevant articles (9 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zhao, Yuqian: 4 articles (01/2022 - 02/2020)
2.	Zhu, Lingjuan: 4 articles (01/2022 - 02/2020)
3.	Liu, Bin: 4 articles (05/2021 - 01/2019)
4.	Li, Lin: 3 articles (05/2021 - 01/2019)
5.	Chen, Xiangyang: 3 articles (07/2020 - 01/2019)
6.	Guo, Shuzhen: 3 articles (07/2020 - 01/2019)
7.	Su, Congping: 3 articles (07/2020 - 01/2019)
8.	Wang, Qing: 3 articles (07/2020 - 01/2019)
9.	Wang, Wei: 3 articles (07/2020 - 01/2019)
10.	Li, Yang: 2 articles (01/2022 - 01/2021)

Related Diseases

1.	Heart Failure 01/01/2019 - "Si-Miao-Yong-An decoction ameliorates cardiac function through restoring the equilibrium of SOD and NOX2 in heart failure mice." 01/01/2019 - "However, the cardioprotective mechanism of SMYAD treating heart failure (HF) remains unclear. " 07/01/2020 - "SMYAD improved cardiac fibrosis and heart failure by inhibition of TGF-β1/Smad and TGF-β1/TAK1/p38 pathway. " 01/01/2022 - "Taken together, the main active components AC and 3,5-DiCQA of SMYAD inhibit the excessive autophagic cell death and apoptosis induced by ISO by inhibiting the PDE5A-AKT and TLR4-NOX4 pathways, thereby reducing myocardial inflammation and improving heart function to alleviate and treat a rat ISO-induced heart failure model and cell heart failure models. " 02/10/2020 - "SMYAD was able to improve the heart function in ISO induced heart failure rat model via protecting rat from developing cardiac hypertrophy and fibrosis. "
2.	Inflammation (Inflammations) 07/25/2023 - "Simiao Yong'an decoction (SMYAD) has the efficacy of anti-inflammation, improving coagulation and microcirculation, which is applicable for the clinical assistance treatment of sepsis. " 01/01/2022 - "Taken together, the main active components AC and 3,5-DiCQA of SMYAD inhibit the excessive autophagic cell death and apoptosis induced by ISO by inhibiting the PDE5A-AKT and TLR4-NOX4 pathways, thereby reducing myocardial inflammation and improving heart function to alleviate and treat a rat ISO-induced heart failure model and cell heart failure models. " 01/01/2021 - "These results indicate that SMYAD attenuated DR development through suppressing retinal inflammation and angiogenesis via abrogating NFκB-TNFα and HIF1α-VEGF signal pathways." 12/01/2023 - "We found that the mechanism SMYAD in TAO therapy was primarily associated with inflammation and angiogenesis by constructing multiple networks. " 01/01/2021 - "Network pharmacology results demonstrated that regulating inflammation, immune responses, and angiogenesis might be associated with the efficacy of SMYAD in alleviating DR, in which the tumor necrosis factor (TNF) and hypoxia inducible factor 1 (HIF1) signal pathways were involved. "
3.	Fibrosis (Cirrhosis) 07/01/2020 - "SMYAD significantly improved cardiac function, increased left ventricle ejection fraction, and decreased fibrosis area and αSMA expression. " 10/01/2020 - "Taken together, these results demonstrate that SMYAD may be a new candidate agent by regulating AMPK-driven Akt/mTOR and TGF-β/SMAD3 pathways for potential therapeutic implications of myocardial fibrosis." 10/01/2020 - "The anti-fibrosis effects of SMYAD have been evaluated; however, its intricate mechanisms remain to be clarified. " 07/01/2020 - "Taken together, these results indicate that SMYAD might be a promising therapeutic agent against cardiac fibrosis." 07/01/2020 - "SMYAD improved cardiac fibrosis and heart failure by inhibition of TGF-β1/Smad and TGF-β1/TAK1/p38 pathway. "
4.	Ischemia 01/01/2021 - "This might be the reason why SMYAD protected myocardial tissue and improved cardiac function in mice with ischemia/reperfusion." 01/01/2022 - "HJ11 is a novel traditional Chinese medicine developed from the appropriate addition and reduction of Si-Miao-Yong-An decoction, which has been commonly used to treat ischemia-reperfusion (I/R) injury in the clinical setting. " 01/01/2021 - "The aim of this study was to determine whether Si-Miao-Yong-An decoction (SMYAD) could protect cardiomyocytes from ischemia/reperfusion (I/R) injury and its underlying mechanisms. "
5.	Atherosclerosis 01/01/2022 - "Simiao Yong'an decoction (SMYAD), a classic traditional Chinese medicine formula, has been used to treat atherosclerosis (AS) in clinical in China, but its therapeutic mechanism and pharmacodynamic material basis are not clear. " 12/01/2023 - "Novel treatment from a botanical formulation Si-Miao-Yong-an decoction inhibits vasa vasorum angiogenesis and stabilizes atherosclerosis plaques via the Wnt1/β-catenin signalling pathway." 08/10/2021 - "To explore the effects of SMYAD on the pathological changes of atherosclerosis (AS) and the differentiation of monocytes, macrophages, and regulatory T (Treg) cells in apolipoprotein E knockout (ApoE-/-) mice. "

Related Drugs and Biologics

1.	Hypoxia-Inducible Factor 1
2.	Catenins
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	si-miao-yong-an decoction
5.	Isoproterenol (Isoprenaline)
6.	Adrenergic Receptors (Adrenergic Receptor)
7.	Messenger RNA (mRNA)
8.	Collagen
9.	Atrial Natriuretic Factor (ANF)
10.	Therapeutic Uses

Related Therapies and Procedures

1.	Chinese Traditional Medicine (Traditional Chinese Medicine)
2.	Therapeutics